Sleep propensity at daytime as assessed by Multiple Sleep Latency Tests (MSLT) in patients with schizophrenia increases with clozapine and olanzapine

Schizophrenia Research

Volumn 135, Issue 1-3, 2012, Pages 123-127

  Kluge, Michael ^a,b   Himmerich, Hubertus ^a   Wehmeier, Peter M ^c   Rummel Kluge, Christine ^a,d   Dalal, Mira ^b   Hinze Selch, Dunja ^e   Kraus, Thomas ^f   Dittmann, Ralf W ^c   Pollmächer, Thomas ^b,g   Schuld, Andreas ^g  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e Fachklinik St Marienstift   (Germany)

^f Frankenalb Klinik   (Germany)

^g KLINIKUM INGOLSTADT   (Germany)

Author keywords

Atypical antipsychotics; Schizophrenia; Sedation; Sleepiness

Indexed keywords

CLOZAPINE; LORAZEPAM; OLANZAPINE;

ADULT; AGED; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL ARTICLE; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; EVENING DOSAGE; FATIGUE; FEMALE; HUMAN; MALE; MORNING DOSAGE; MULTIPLE SLEEP LATENCY TEST; NEUROLOGIC EXAMINATION; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REM SLEEP; SCHIZOPHRENIA; SEDATION; SIDE EFFECT;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; DISORDERS OF EXCESSIVE SOMNOLENCE; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYSOMNOGRAPHY; PSYCHIATRIC STATUS RATING SCALES; REACTION TIME; SCHIZOPHRENIA; SLEEP STAGES; STATISTICS AS TOPIC; TIME FACTORS; YOUNG ADULT;

EID: 84857233625     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2011.12.017     Document Type: Article

References (37)

1. Arand D., Bonnet M., Hurwitz T., Mitler M., Rosa R., Sangal R.B. The clinical use of the MSLT and MWT. Sleep 2005, 28:123-144.
2. Betensky J.D., Robinson D.G., Gunduz-Bruce H., Sevy S., Lencz T., Kane J.M., Malhotra A.K., Miller R., McCormack J., Bilder R.M., Szeszko P.R. Patterns of stress in schizophrenia. Psychiatry Res. 2008, 160:38-46.
3. Bonnet M.H., Arand D.L. Level of arousal and the ability to maintain wakefulness. J. Sleep Res. 1999, 8:247-254.
4. Buchanan R.W. Clozapine: efficacy and safety. Schizophr. Bull. 1995, 21:579-591.
5. Bymaster F.P., Calligaro D.O., Falcone J.F., Marsh R.D., Moore N.A., Tye N.C., Seeman P., Wong D.T. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996, 14:87-96.
6. Carskadon M.A., Dement W.C., Mitler M.M., Roth T., Westbrook P.R., Keenan S. Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness. Sleep 1986, 9:519-524.
7. Carter J.D., Bizzell J., Kim C., Bellion C., Carpenter K.L., Dichter G., Belger A. Attention deficits in schizophrenia-preliminary evidence of dissociable transient and sustained deficits. Schizophr. Res. 2010, 122:104-112.
8. Chouinard S., Poulin J., Stip E., Godbout R. Sleep in untreated patients with schizophrenia: a meta-analysis. Schizophr. Bull. 2004, 30:957-967.
9. Dinzeo T.J., Cohen A.S., Nienow T.M., Docherty N.M. Stress and arousability in schizophrenia. Schizophr. Res. 2004, 71:127-135.
10. Fioravanti M., Carlone O., Vitale B., Cinti M.E., Clare L. A meta-analysis of cognitive deficits in adults with a diagnosis of schizophrenia. Neuropsychol. Rev. 2005, 15:73-95.
11. Geisler P., Tracik F., Crönlein T., Fulda S., Wichniak A., Popp R., Zulley J., Hajak G. The influence of age and sex on sleep latency in the MSLT-30-a normative study. Sleep 2006, 29:687-692.
12. Haas H.L., Sergeeva O.A., Selbach O. Histamine in the nervous system. Physiol. Rev. 2008, 88:1183-1241.
13. Johns M.W. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991, 14:540-545.
14. Johns M.W. Sensitivity and specificity of the multiple sleep latency test (MSLT), the maintenance of wakefulness test and the epworth sleepiness scale: failure of the MSLT as a gold standard. J. Sleep Res. 2000, 9:5-11.
15. Karagianis J., Grossman L., Landry J., Reed V.A., de H.L., Maguire G.A., Hoffmann V.P., Milev R. A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: the PLATYPUS Study. Schizophr. Res. 2009, 113:41-48.
16. Kasravi N., Legault G., Jewell D., Murray B.J. Minimal impact of inadvertent sleep between naps on the MSLT and MWT. J. Clin. Neurophysiol. 2007, 24:363-365.
17. Kluge M., Wehmeier P.M., Dittmann R.W., Langer F., Czekalla J., Lehmann M., Kessler F.H., Beyenburg S., Naber D. A simple switching strategy for inadequately treated patients with schizophrenia to olanzapine: changes in psychopathology and subjective well-being. Pharmacopsychiatry 2005, 38:6-12.
18. Kluge M., Schuld A., Himmerich H., Dalal M., Schacht A., Wehmeier P.M., Hinze-Selch D., Kraus T., Dittmann R.W., Pollmächer T. Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study. J. Clin. Psychopharmacol. 2007, 27:662-666.
19. Kluge M., Schüssler P., Dresler M., Yassouridis A., Steiger A. Sleep onset REM periods in obsessive compulsive disorder. Psychiatry Res. 2007, 152:29-35.
20. Kluge M., Schuld A., Schacht A., Himmerich H., Dalal M.A., Wehmeier P.M., Hinze-Selch D., Kraus T., Dittmann R.W., Pollmächer T. Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever. Psychoneuroendocrinology 2009, 34:118-128.
21. Kumar A., Greden J., Grunhaus L., Eiser A. Sleep-onset REM period in paranoid schizophrenia. Biol. Psychiatry 1985, 20:815-816.
22. Leucht S., Komossa K., Rummel-Kluge C., Corves C., Hunger H., Schmid F., Asenjo L.C., Schwarz S., Davis J.M. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am. J. Psychiatry 2009, 166:152-163.
23. Mathis J., Hess C.W. Sleepiness and vigilance tests. Swiss Med. Wkly. 2009, 139:214-219.
24. McEvoy J.P., Lieberman J.A., Perkins D.O., Hamer R.M., Gu H., Lazarus A., Sweitzer D., Olexy C., Weiden P., Strakowski S.D. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am. J. Psychiatry 2007, 164:1050-1060.
25. Mignot E., Lin L., Finn L., Lopes C., Pluff K., Sundstrom M.L., Young T. Correlates of sleep-onset REM periods during the Multiple Sleep Latency Test in community adults. Brain 2006, 129:1609-1623.
26. Nakagami E., Hoe M., Brekke J.S. The prospective relationships among intrinsic motivation, neurocognition, and psychosocial functioning in schizophrenia. Schizophr. Bull. 2010, 36:935-948.
27. Oken B.S., Salinsky M.C., Elsas S.M. Vigilance, alertness, or sustained attention: physiological basis and measurement. Clin. Neurophysiol. 2006, 117:1885-1901.
28. Pollmächer T., Mullington J., Lauer C.J. REM sleep disinhibition at sleep onset: a comparison between narcolepsy and depression. Biol. Psychiatry 1997, 42:713-720.
29. Poulin J., Chouinard S., Pampoulova T., Lecomte Y., Stip E., Godbout R. Sleep habits in middle-aged, non-hospitalized men and women with schizophrenia: a comparison with healthy controls. Psychiatry Res. 2010, 179:274-278.
30. Rechtschaffen A., Kales A. A Manual of Standardized Terminology 1968, Techniques and Scoring System for Sleep Stages of Hunman Subjects Brain Information Service Brain Research Institute, University of California, Los Angeles.
31. Rummel-Kluge C., Komossa K., Schwarz S., Hunger H., Schmid F., Lobos C.A., Kissling W., Davis J.M., Leucht S. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr. Res. 2010, 123:225-233.
32. Rummel-Kluge C., Komossa K., Schwarz S., Hunger H., Schmid F., Kissling W., Davis J.M., Leucht S. Second-Generation Antipsychotic Drugs and Extrapyramidal Side Effects: A Systematic Review and Meta-analysis of Head-to-Head Comparisons. Schizophr Bull. 2012, 38:167-177.
33. Schulz H., Lund R. Sleep onset REM episodes are associated with circadian parameters of body temperature. A study in depressed patients and normal controls. Biol. Psychiatry 1983, 18:1411-1426.
34. Singh M., Drake C.L., Roth T. The prevalence of multiple sleep-onset REM periods in a population-based sample. Sleep 2006, 29:890-895.
35. Sullivan S.S., Kushida C.A. Multiple sleep latency test and maintenance of wakefulness test. Chest 2008, 134:854-861.
36. Wichniak A., Szafranski T., Wierzbicka A., Waliniowska E., Jernajczyk W. Electroencephalogram slowing, sleepiness and treatment response in patients with schizophrenia during olanzapine treatment. J. Psychopharmacol. 2006, 20:80-85.
37. Wichniak A., Skowerska A., Chojnacka-Wojtowicz J., Taflinski T., Wierzbicka A., Jernajczyk W., Jarema M. Actigraphic monitoring of activity and rest in schizophrenic patients treated with olanzapine or risperidone. J. Psychiatr. Res. 2011, 45:1381-1386.